The seventh batch of collecting bid results official announcement, the supply and province confirmed by the selected pharmaceutical companies

The seventh batch of centralized procurement of the nation ’s drug was officially announced.

On July 18, the National Organization Pharmaceutical Cooperative Purchasing Office announced the official selection results of the seventh batch of centralized nationwide pharmaceutical procurement through Shanghai Sunshine Pharmaceutical Procurement Network. The announcement stated that the selection results in this collection will be implemented in November 2022, and the specific implementation date will be issued by various places.

According to the data previously released by the National Medical Insurance Bureau, 488 products from 295 companies participated in the bidding for the collection. The 327 products of 217 companies were qualified to be selected. In the end %.

Compared with the list of selected enterprises announced on the day of July 12, the official selection results announced the supply provinces and provinces of each breed of each breed.

Preparation area is a major innovation of this collection of collection rules. The main purpose is to avoid the "disconnection" phenomenon that has appeared in the past few rounds of collection. In accordance with the rules, the proposed enterprise is planned to conduct a regional confirmation procedure after confirmation of the main region. The region of each selected enterprise must be different from its main region. If the number of enterprises is selected is one, there is no need to participate in the preparation area to confirm.

Regarding the choice of regional, some representatives of enterprises participating in the collection told reporters that they must choose to choose from Beijing, Shanghai, and other areas. According to the amount of reporting in a certain region, it will also refer to the company's own layout in the national market. And control.

In accordance with the seventh batch of collecting rules, in addition to the special requirements of some varieties, most varieties agreed in the first year of procurement in accordance with the following rules: If the number of enterprises in the actual reality of the country is 1, the first year agreed to purchase the calculation base of the volume calculation base year 50%; if the number of enterprises in actual actual selection in the country is 2, 60%of the calculation base agreed in the first year; if the number of companies in the country is 3, it is 70%of the number of procurement calculations agreed in the first year; For 4 or more, 80%of the calculation base agreed in the first year.

Judging from the latest announcement of the selection, the selection companies of multiple popular varieties are different in regional choices.

"Influenza Pharmaceuticals" Oshwa Weil 75mg*30 specifications, Guangdong Dongguang Pharmaceutical Co., Ltd. reported the minimum price of 29.97 yuan/box, with an average unit price of only 0.999 yuan/grain. The maximum effective declaration price of 13.01 yuan decreased by 92%. Supply provinces include Shandong Province, Hubei Province, Guangdong Province, and Chongqing; the provinces choose Shanxi Province, Jiangsu, Jiangxi Province, and Henan Province.

The lowest quotation of Omeprazole injection is Harbin Sanlian Pharmaceutical Co., Ltd., 40mg*10 bottles/box, 6.94 yuan, an average of less than 7 cents per bottle, and a price reduction of 95.04%. The provinces selected by the company are Beijing, Shanghai, Jiangsu, and Shaanxi Province. The provinces include the Inner Mongolia Autonomous Region, Shandong, Chongqing, and Yunnan Province.

A total of 7 companies have won the bid for the first targeted Delonalinib of liver cancer. The National Medical Insurance Bureau introduced that each capsule decreased from an average of 108 yuan to an average of 18 yuan. One treatment cycle can save 8,100 yuan. Among them, Xianyou Pharmaceuticals also reported the lowest price of 3.2 yuan/piece (specification 4mg, 30 capsules per box), compared with the highest effective declaration price of 108 yuan, a decrease of 97%. 100 yuan. Some people in the industry directly shouted that the price of an anti -cancer drug is not as good as a ice cream.

From the perspective of the region, the provinces selected by Xianyou Pharmaceuticals include Shanxi Province, Shanghai, Anhui Province, Jiangxi Province, Guangdong, and Qinghai Province. , Henan Province.

The United States of Kinsent Hydrochloride is the first -line therapy drug of Aldzheimer's disease. There are 6 companies selected this time, of which 7mg*30 capsules/bottle specifications. Less than 1.3 yuan, the highest effective declaration price of 9.7889 yuan, a decrease of more than 87%. The bid in the same specifications is Qingdao Baiyang Pharmaceutical, with a price of 79 yuan and a single capacity of more than 73%. The provinces of Renfu Pharmaceuticals are Jilin Province, Henan Province, Guangdong Province, Sichuan Province, Shaanxi Province, Xinjiang (including Corps). Province.

The overall decrease of the collection was lower than the first six batches of 53%, but the quotation of the above varieties was still attracted much attention. For patients, the quality of drugs is more concerned about the quality of drugs. For enterprises, whether a large decline can guarantee profits.

Baiyang Pharmaceutical previously told reporters that there are two high -quality products in Baiyang Pharmaceutical, which is a high -quality generic drug, and has the same effect as the original drug. After entering the collection medicine. Xianyou Pharmaceuticals also publicly stated to the media that in the pricing of Lunpetinib this time, the historical data of the previous quotation of the friends who participated in the bidding company, as well as the patient's psychological expected price of this basic targeted drug, the company After the evaluation, it is considered that the price of the drug is enough to be affordable on the basis of ensuring basic profits.

Ping An Securities Research Report believes that from two aspects, we should pay attention to the marginal impact of Jizhi on enterprises.The first is to pay attention to the bare -footed enterprises that collect and release. These companies usually have a rich imitation drug echelon. After the products are approved, they have a consistent evaluation.Enterprise is represented.The second is to pay attention to the weakened shoes wearing weakening on the impact of the performance, and grasp the inflection point of the new variety increasing more than the loss of stock varieties.CITIC Securities Research Report pointed out that the focus of volume procurement has gradually shifted to the field of injection, and the pace of progress has gradually accelerated.It is expected that the major varieties (including injections) with high clinical drugs and high procurement amounts will no longer be the profit growth point of pharmaceutical companies.Bringing volume is more about the cage and birds that promote medical insurance funds and support for the development of innovative drugs.In the future, the importance of the sales capacity of pharmaceutical companies will gradually weaken, and innovation and transformation are expected to be the main way for pharmaceutical companies to enhance competitiveness.

Source: Surging News

- END -